HANGZHOU, China, May 7, 2023 /PRNewswire/ — Bliss Biopharmaceutical (Hangzhou) Co., Ltd, (“BlissBio”), a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a clinical trial collaboration agreement with an option for a strategic collaboration with Eisai Co.,Ltd. (“Eisai”), for BB-1701, an eribulin payload-based ADC targeting human epidermal growth factor receptor 2 (HER2) for the treatment of cancer.
This collaboration with Eisai is an important advance in BlissBio’s corporate development plan to advance BB-1701 globally and help advance BB-1701 into late-stage development. BB-1701 is currently in Phase I/II studies in the US and China with over a hundred patients given various types of cancer.
Under the terms of the agreement, BlissBio will receive upfront and milestone payments, and BlissBio and Eisai will conduct joint development activities related to BB-1701 during an option period. If Eisai exercises its option to enter into a strategic collaborative license for BB-1701, BlissBio will receive an option exercise payment and be eligible for development and commercial milestone payments totaling up to 2 billion dollars, and royalties on sales. If the option is exercised, Eisai will receive worldwide (excluding Greater China) Rights to develop and commercialize BB-1701.
“This clinical collaboration with Eisai, one of the leading Japanese pharmaceutical companies with strong global oncology R&D capabilities, is a significant achievement for BlissBio as it allows us to advance this promising compound, BB-1701,” said Dr. zipper white, CEO of BlissBio. “Through this important partnership, we are committed to working with Eisai to advance the development of BB-1701 for the benefit of patients worldwide.”
BB-1701 is an innovative ADC developed by BlissBio, consisting of anti-HER2 antibody and eribulin. It was designed to…